[ET Net News Agency, 8 September 2021] Morgan Stanley raised its target price for Fosun
Pharma (02196) to HK$61.3 from HK$56 and maintained its "equal-weight" rating.
The research house said it raises its earnings estimates by 2-9% over 2021-2024, mainly
on higher diagnostics and hospital services revenues, and better operating expense ratios.
Together with a slight improvement in working capital metrics, bull/base/bear scenarios
are up by 9-10%. (RC)